Bengel, Frank
Epstein, Jonathan A.
Gropler, Robert
Haberkorn, Uwe
Kramann, Rafael
Lavine, Kory
Leuschner, Florian
Liu, Yongjian
Rosenthal, Nadia
Wu, Hao
Article History
First Online: 1 April 2024
Competing interests
: J.A.E. holds equity in Capstan Therapeutics, a biotechnology company focused on developing mRNA approaches to generate CAR-T cells in vivo. R.K. is the founder and shareholder of Sequantrix GmbH and has grants from Travere Therapeutics, Galapagos, Chugai, AskBio and Novo Nordisk, and is a consultant for Bayer, Pfizer, Novo Nordisk, Hybridize Therapeutics and Gruenenthal. U.H. is one of the inventors of a pending patent application (PCT/EP2019/052952) filed by Universität Heidelberg for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine, and the description of the radiopharmaceuticals for use in the diagnosis or treatment of a disease characterized by overexpression of FAP in this manuscript is related to this patent application. U.H. holds shares of a consultancy group for iTheranostics. Y.L., R.G. and K.L. are inventors on a pending patent application (US17/001,857) filed by Washington University, and methods for detecting CCR2 receptor described in this manuscript are related to this patent application. Other authors declare no competing interests.